Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

Oncogenesis and ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) remain uncertain, between canonical plasmacytoid dendritic cells (pDCs) and AXL+ SIGLEC6+ DCs (AS-DCs). We compared 12 BPDCN to 164 acute leukemia by Affymetrix HG-U133 Plus 2.0 arrays: BPDCN were closer to B-cell acute lymphoblastic leukemia (ALL), with enrichment in pDC, B-cell signatures, vesicular transport, deubiquitination pathways, and AS-DC signatures, but only in some cases. Importantly, 1 T-cell ALL clustered with BPDCN, with compatible morphology, immunophenotype (cCD3+ sCD3- CD123+ cTCL1+ CD304+), and genetics. Many oncogenetic pathways are deregulated in BPDCN compared with normal pDC, such as cell-cycle kinases, and importantly, the transcription factor SOX4, involved in B ontogeny, pDC ontogeny, and cancer cell invasion. High-throughput sequencing (HaloPlex) showed myeloid mutations (TET2, 62%; ASXL1, 46%; ZRSR2, 31%) associated with lymphoid mutations (IKZF1), whereas single-nucleotide polymorphism (SNP) array (Affymetrix SNP array 6.0) revealed frequent losses (mean: 9 per patient) involving key hematological oncogenes (RB1, IKZF1/2/3, ETV6, NR3C1, CDKN2A/B, TP53) and immune response genes (IFNGR, TGFB, CLEC4C, IFNA cluster). Various markers suggest an AS-DC origin, but not in all patients, and some of these abnormalities are related to the leukemogenesis process, such as the 9p deletion, leading to decreased expression of genes encoding type I interferons. In addition, the AS-DC profile is only found in a subgroup of patients. Overall, the cellular ontogenic origin of BPDCN remains to be characterized, and these results highlight the heterogeneity of BPDCN, with a risk of a diagnostic trap.

[1]  M. Duvic,et al.  Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: a national database study. , 2020, Journal of the American Academy of Dermatology.

[2]  M. Mohty,et al.  Plasmacytoid dendritic cell biology and its role in immune‐mediated diseases , 2020, Clinical & translational immunology.

[3]  F. Jardin,et al.  How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? , 2019, Blood advances.

[4]  M. Paulli,et al.  Whole‐genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm , 2019, Genes, chromosomes & cancer.

[5]  M. Konopleva,et al.  Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm , 2019, The American journal of surgical pathology.

[6]  S. Mehdi,et al.  Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia , 2019, BMJ Case Reports.

[7]  I. Amit,et al.  Plasmacytoid dendritic cells develop from Ly6D+ lymphoid progenitors distinct from the myeloid lineage , 2019, Nature Immunology.

[8]  J. Vial,et al.  Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm , 2019, British Journal of Haematology.

[9]  A. Iwama,et al.  Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm , 2019, Nature Communications.

[10]  S. Pileri,et al.  Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target , 2018, Haematologica.

[11]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[12]  L. Medeiros,et al.  Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. , 2018, Leukemia research.

[13]  R. Nilsson,et al.  Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment , 2018, Cell Death & Disease.

[14]  E. Solary,et al.  Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms , 2018, Blood Cancer Journal.

[15]  Robert Ivanek,et al.  Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells , 2018, Nature Immunology.

[16]  K. Ohshima,et al.  Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response , 2018, Leukemia.

[17]  Haley O. Tucker,et al.  Lymphoid origin of intrinsically activated plasmacytoid dendritic cells in mice , 2018, bioRxiv.

[18]  Lisa E. Wagar,et al.  High‐Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization , 2017, Immunity.

[19]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[20]  F. Garnache-Ottou,et al.  Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm , 2017, Haematologica.

[21]  H. Tien,et al.  Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish , 2017, Blood Cancer Journal.

[22]  Evan W. Newell,et al.  Mapping the human DC lineage through the integration of high-dimensional techniques , 2017, Science.

[23]  Rohini Sharma,et al.  Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1 , 2017, Cellular Oncology.

[24]  N. Hacohen,et al.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors , 2017, Science.

[25]  Y. Okuno,et al.  Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm , 2017, Leukemia.

[26]  Xiangyue Zhang,et al.  A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes , 2017, Proceedings of the National Academy of Sciences.

[27]  B. Falini,et al.  Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin , 2017, Leukemia.

[28]  E. Macintyre,et al.  LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. , 2016, Blood.

[29]  M. Ferrer,et al.  A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. , 2016, Cancer cell.

[30]  Z. Hu,et al.  Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia. , 2016, Blood.

[31]  F. Jardin,et al.  Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. , 2016, Blood.

[32]  L. Thomas,et al.  Blastic plasmacytoid dendritic cell neoplasm following Waldenström macroglobulinemia , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[33]  Aaron T. L. Lun,et al.  RUNX2 Mediates Plasmacytoid Dendritic Cell Egress from the Bone Marrow and Controls Viral Immunity. , 2016, Cell reports.

[34]  F. Jardin,et al.  Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN , 2015 .

[35]  Rob Pieters,et al.  Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia , 2015, Haematologica.

[36]  G. Bendas,et al.  Vascular cell adhesion molecule‐1 (VCAM‐1)—An increasing insight into its role in tumorigenicity and metastasis , 2015, International journal of cancer.

[37]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[38]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[39]  W. Klapper,et al.  Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm , 2014, Oncotarget.

[40]  J. Cigudosa,et al.  Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm , 2014, Leukemia.

[41]  S. Pileri,et al.  Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition , 2014, Leukemia.

[42]  L. Jeffrey Medeiros,et al.  TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow , 2013, American journal of hematology.

[43]  T. Petrella,et al.  Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients , 2013, The British journal of dermatology.

[44]  Jian-Bing Fan,et al.  The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment , 2013, Nature Immunology.

[45]  M. Piris,et al.  SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. , 2013, Blood.

[46]  B. Johansson,et al.  Homozygous deletions of CDKN2A are present in all dic(9;20)(p13·2;q11·2)‐positive B‐cell precursor acute lymphoblastic leukaemias and may be important for leukaemic transformation , 2012, British journal of haematology.

[47]  M. Saegusa,et al.  Sox4 functions as a positive regulator of β-catenin signaling through upregulation of TCF4 during morular differentiation of endometrial carcinomas , 2012, Laboratory Investigation.

[48]  Emily G Tillmaand,et al.  HOXA9 Methylation by PRMT5 Is Essential for Endothelial Cell Expression of Leukocyte Adhesion Molecules , 2012, Molecular and Cellular Biology.

[49]  M. Paulli,et al.  Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. , 2011, Blood.

[50]  N. Jenkins,et al.  Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. , 2011, Blood.

[51]  K. Lewis,et al.  Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells. , 2010, Immunity.

[52]  E. Macintyre,et al.  Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia , 2009, British journal of haematology.

[53]  T. Matsui,et al.  CD2 Distinguishes Two Subsets of Human Plasmacytoid Dendritic Cells with Distinct Phenotype and Functions1 , 2009, The Journal of Immunology.

[54]  F. Jardin,et al.  Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease , 2009, Leukemia.

[55]  E. Kimby,et al.  TCL1A expression delineates biological and clinical variability in B-cell lymphoma , 2009, Modern Pathology.

[56]  F. Jardin,et al.  Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease , 2009, Leukemia.

[57]  Manfred Lehner,et al.  Transcription Factor E2-2 Is an Essential and Specific Regulator of Plasmacytoid Dendritic Cell Development , 2008, Cell.

[58]  Jorng-Tzong Horng,et al.  Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma , 2008, Oncogene.

[59]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[60]  Melanie Bahlo,et al.  Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo , 2007, Nature Immunology.

[61]  D. Jarrossay,et al.  Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow , 2007, Nature Immunology.

[62]  R. Willemze,et al.  Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. , 2007, Blood.

[63]  B. Drénou,et al.  Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. , 2004, Blood.

[64]  E. Devilard,et al.  Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. , 2005, International journal of oncology.

[65]  E. Macintyre,et al.  Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. , 2003, Blood.

[66]  T. Petrella,et al.  `Agranular CD4+ CD56+ Hematodermic Neoplasm' (Blastic NK-Cell Lymphoma) Originates From a Population of CD56+ Precursor Cells Related to Plasmacytoid Monocytes , 2002, The American journal of surgical pathology.

[67]  J. Rowley,et al.  Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression. , 2002, Cancer genetics and cytogenetics.

[68]  J. Manning,et al.  CD56+ TdT+ blastic natural killer cell tumor of the skin , 2002, Cancer.

[69]  R. Gressin,et al.  Identification of a leukemic counterpart of the plasmacytoid dendritic cells. , 2001, Blood.

[70]  R. Warnke,et al.  Composite dendritic cell neoplasm (NOS) and small lymphocytic lymphoma. , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[71]  A. Órfão,et al.  CD123 hiDendritic Cell Lymphoma: An Unusual Case of Non-Hodgkin Lymphoma , 1999, Annals of Internal Medicine.

[72]  D. Wotton,et al.  The High Mobility Group Transcription Factor, SOX4, Transactivates the Human CD2 Enhancer (*) , 1995, The Journal of Biological Chemistry.

[73]  D. Schadendorf,et al.  Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. , 1995, Journal of the National Cancer Institute.